share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144:擬議出售證券
SEC announcement ·  04/15 16:29
Moomoo AI 已提取核心訊息
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 19,582 common shares on April 15, 2024, with an aggregate market value of approximately $1.17 million. The shares to be sold were acquired on the same date through a stock option exercise, with the securities obtained directly from the issuer and paid for in cash. Over the past three months, Kulkarni has sold a total of 130,755 shares of CRISPR Therapeutics, generating gross proceeds of nearly $8.95 million.
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 19,582 common shares on April 15, 2024, with an aggregate market value of approximately $1.17 million. The shares to be sold were acquired on the same date through a stock option exercise, with the securities obtained directly from the issuer and paid for in cash. Over the past three months, Kulkarni has sold a total of 130,755 shares of CRISPR Therapeutics, generating gross proceeds of nearly $8.95 million.
CRISPR Therapeutics AG高管兼董事薩瑪斯·庫爾卡尼定於2024年4月15日出售19,582股普通股,總市值約爲117萬美元。待售股票於同日通過股票期權行使收購,證券直接從發行人處獲得並以現金支付。在過去的三個月中,庫爾卡尼共出售了CRISPR Therapeutics的130,755股股票,總收益接近895萬美元。
CRISPR Therapeutics AG高管兼董事薩瑪斯·庫爾卡尼定於2024年4月15日出售19,582股普通股,總市值約爲117萬美元。待售股票於同日通過股票期權行使收購,證券直接從發行人處獲得並以現金支付。在過去的三個月中,庫爾卡尼共出售了CRISPR Therapeutics的130,755股股票,總收益接近895萬美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息